News Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 05/12/2025 GMT			5-day change	1st Jan Change
1,010.31 ^USD	-0.41%		-6.06%	+30.87%

12-05	India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact	RE
12-04	Novo Nordisk gears up for Ozempic launch in India, sources say	RE

India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact	12-05	RE
Novo Nordisk gears up for Ozempic launch in India, sources say	12-04	RE
BMO Capital Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Outperform Rating	12-04	MT
Novo Nordisk to Launch Ozempic in India in Coming Weeks - Reuters	12-04	FW
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment	12-04	RE
Eli Lilly and : Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers	12-03	PU
Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)	12-03	CI
Eli Lilly Says FDA Expands Jaypirca Label in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	12-03	MT
Eli Lilly Gets Expanded FDA Approval for Cancer Drug Jaypirca	12-03	DJ
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor	12-03	PR
Novo Nordisk gears up for December Ozempic launch in India, sources say	12-03	RE
FDA grants traditional approval to pirtobrutinib	12-03	RE
Excelsior Sciences announced that it has received $70 million in funding from a group of investors	12-03	CI
Alnylam Pharmaceuticals Announces Changes to Board of Directors	12-03	CI
Eli Lilly not yet ready to unfreeze UK investments, says pharma boss - FT	12-03	RE
Excelsior Sciences raises $95 million to speed small molecule drug development using AI	12-03	RE
Wolfe Research Adjusts PT on Eli Lilly and Company to $1,250 From $1,050, Maintains Outperform Rating	12-03	MT
Guggenheim Adjusts Price Target on Eli Lilly and Company to $1,163 From $1,036, Maintains Buy Rating	12-03	MT
Eli Lilly's Weight Loss Drug Mounjaro Becomes Sweden's Best-Selling Medication in November	12-03	FW
Eli Lilly and Company Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 10:30 AM	12-02
Lilly lowers the price of Zepbound single-dose vials	12-02	AQ
Eli Lilly Price Target, Earnings Estimates Up as Berenberg Highlights Strong Q3, Upcoming Catalysts	12-02	MT
Berenberg Adjusts Price Target on Eli Lilly and Co. to $950 From $830, Maintains Hold Rating	12-02	MT
Healthcare Stocks Reverse Some Recent Gains -- Healthcare Roundup	12-01	DJ
FTSE 100 down as US manufacturing growth slows	12-01	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

December 01, 2025 at 03:39 pm

Is it back to square one for Eli Lilly?

August 07, 2025 at 04:20 pm